Dragon Pharmaceuticals
Dragon Pharmaceuticals Inc. is a global biopharmaceutical and pharmaceutical company specializing in anabolic steroids, peptides, growth hormones (HGH), SARMs, SERMs, and aromatase inhibitors—ensuring GMP-certified quality for athletes, bodybuilders, and medical professionals worldwide. The company focuses on high-quality production, innovation, and expanding its product range to include pharmaceutical-grade compounds and biosimilars. It operates manufacturing facilities in China and has a strong international presence, supplying trusted pharmaceutical solutions worldwide.
Industries
Nr. of Employees
medium (51-250)
Dragon Pharmaceuticals
Vancouver, Alberta, Canada, North America
Products
Erythropoietin (EPO)
Recombinant erythropoietin produced at commercial scale for treatment of anemia related to renal failure, chemotherapy and surgery; product approved in multiple international markets.
Recombinant G-CSF (in-licensed for international markets)
Recombinant granulocyte colony-stimulating factor obtained via in-licensing for commercialization outside China.
Pipeline biologics (TPO, insulin, slow-release EPO)
Development-stage therapeutic proteins including thrombopoietin, recombinant insulin and slow-release EPO formulations undergoing preclinical work and formulation development.
Performance-enhancing and peptide product categories
Commercial offerings of anabolic steroids, peptides, growth hormones, selective androgen receptor modulators (SARMs), selective estrogen receptor modulators (SERMs) and aromatase inhibitors.
Chemical intermediates and APIs (clavulanic acid, 7-ACA)
Bulk chemical intermediate and API production for use in formulation and supply, including clavulanic acid and 7-ACA.
Erythropoietin (EPO)
Recombinant erythropoietin produced at commercial scale for treatment of anemia related to renal failure, chemotherapy and surgery; product approved in multiple international markets.
Recombinant G-CSF (in-licensed for international markets)
Recombinant granulocyte colony-stimulating factor obtained via in-licensing for commercialization outside China.
Pipeline biologics (TPO, insulin, slow-release EPO)
Development-stage therapeutic proteins including thrombopoietin, recombinant insulin and slow-release EPO formulations undergoing preclinical work and formulation development.
Performance-enhancing and peptide product categories
Commercial offerings of anabolic steroids, peptides, growth hormones, selective androgen receptor modulators (SARMs), selective estrogen receptor modulators (SERMs) and aromatase inhibitors.
Chemical intermediates and APIs (clavulanic acid, 7-ACA)
Bulk chemical intermediate and API production for use in formulation and supply, including clavulanic acid and 7-ACA.
Services
On-site GMP manufacturing of sterile and non-sterile pharmaceutical products with automated filling, inspection and sterile-filling capabilities.
Development of high-yield cell lines, expression optimization, preclinical-scale testing and process transfer for recombinant proteins.
Formulation development (including slow-release formats) and support for clinical program execution and regulatory submission activities.
Preparation and coordination of regulatory submissions and licensing strategies across China and international jurisdictions.
In-licensing and out-licensing of pharmaceutical products and establishment of international licensing agreements for distribution.
Production and supply of bulk pharmaceutical chemicals and intermediates (for example clavulanic acid and 7-ACA) at dedicated chemical facilities.
On-site GMP manufacturing of sterile and non-sterile pharmaceutical products with automated filling, inspection and sterile-filling capabilities.
Development of high-yield cell lines, expression optimization, preclinical-scale testing and process transfer for recombinant proteins.
Formulation development (including slow-release formats) and support for clinical program execution and regulatory submission activities.
Preparation and coordination of regulatory submissions and licensing strategies across China and international jurisdictions.
In-licensing and out-licensing of pharmaceutical products and establishment of international licensing agreements for distribution.
Production and supply of bulk pharmaceutical chemicals and intermediates (for example clavulanic acid and 7-ACA) at dedicated chemical facilities.
Expertise Areas
- Bioprocessing and scale-up
- Recombinant protein therapeutics
- Generic biologics manufacturing
- Cell-line development
Key Technologies
- Recombinant protein expression
- Proprietary DNA vector platforms
- CHO cell line technology
- Pichia yeast expression systems
News & Updates
Dragon Pharma Annual Shareholders Meeting 2005
The annual shareholders meeting was held on August 12, 2005, with proposals including election of directors, amendments to corporate documents, and adoption of stock plans.
Results for 2004 Financial Year
Dragon Pharma reported revenues of $3.71 million with a net loss of $0.94 million, and announced progress in international markets and new production facilities.
Acquisition of Oriental Wave Holding Limited
Dragon completed the acquisition of Oriental Wave, expanding into diversified biotech, chemical, and pharma businesses with multiple manufacturing facilities.
Business Strategy Update 2004
The company announced a focus on sales capacity, product development, and international expansion, including new facilities and licensing agreements.
Private Placements and Capital Raising
Dragon Pharma completed several private placements raising up to $10.6 million to fund expansion and development of biotech and generic products.
Dragon Pharma's Strategic Growth and International Expansion
An overview of Dragon Pharma's efforts to expand its product portfolio, manufacturing capacity, and global presence in the biotech and pharmaceutical sectors.
Dragon Pharma Annual Shareholders Meeting 2005
The annual shareholders meeting was held on August 12, 2005, with proposals including election of directors, amendments to corporate documents, and adoption of stock plans.
Results for 2004 Financial Year
Dragon Pharma reported revenues of $3.71 million with a net loss of $0.94 million, and announced progress in international markets and new production facilities.
Acquisition of Oriental Wave Holding Limited
Dragon completed the acquisition of Oriental Wave, expanding into diversified biotech, chemical, and pharma businesses with multiple manufacturing facilities.
Business Strategy Update 2004
The company announced a focus on sales capacity, product development, and international expansion, including new facilities and licensing agreements.
Private Placements and Capital Raising
Dragon Pharma completed several private placements raising up to $10.6 million to fund expansion and development of biotech and generic products.
Dragon Pharma's Strategic Growth and International Expansion
An overview of Dragon Pharma's efforts to expand its product portfolio, manufacturing capacity, and global presence in the biotech and pharmaceutical sectors.